INST 0603C Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer
Overview
Chart Review of patients with pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
Full Title of Study: “INST 0603C Chart Review on Patients With Unresectable/Metastatic Pancreatic Cancer Treated in the UNM Cancer”
Study Type
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: December 2006
Detailed Description
Chart Review to describe the clinical outcomes in patients pancreatic cancer treated with combination of irinotecan, oxaliplatin and cetuximab.
Clinical Trial Outcome Measures
Primary Measures
- Time to Death
- Time Frame: From date of treatment until time of death
- Length of survival of patients treated with a combination of Oxaliplatin 60mg/m2, Irinotecan 90mg/m2, and Cetuximab 250 mg/m2 delivered every other week.
Participating in This Clinical Trial
Inclusion Criteria
Patients with unresectable/metastatic pancreatic cancer treated in the UNM Cancer Research and Treatment Center. Exclusion Criteria:
Not specified.
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
Investigator Details
- Lead Sponsor
- University of New Mexico
- Provider of Information About this Clinical Study
- Sponsor
- Overall Official(s)
- Fa-Chyi Lee, MD, Principal Investigator, University of New Mexico
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.